ERBB2 and neoplasm: In HR‐negative invasive breast tumors, higher quantity of tumor‐infiltrating lymphocytes (TILs) has strong prognostic associations, particularly in the setting of early‐stage triple‐negative breast carcinomas (TNBC)9 and human epidermal growth factor receptor 2 (HER2)—positive breast carcinomas10 treated with adjuvant chemotherapy, while TILs represent a promising new morphologic biomarker associated with poor outcome of ILC.4